Background & Aims Pharmacological management of obesity improves outcomes and
decreases the risk of obesity-related complications. This American Gastroenterological …

The following literature search is in response to inquiries made to the American Society for
Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in …

Background Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver
disease affecting approximately 25% of adults in the western world. Intragastric balloon …

Introduction Obesity drives type 2 diabetes (T2DM) development. Laparoscopic adjustable
gastric banding (LAGB) has lower weight reduction than other bariatric procedures …

Abstract Purpose of Review To comprehensively summarize the current body of literature on
the topic of adjuvant and neoadjuvant pharmacotherapy used in combination with bariatric …

Obesity is a chronic disease that affects over 795 million people worldwide. Bariatric surgery
is an effective therapy to combat the epidemic of clinically severe obesity, but it is only …

Materials and Methods: This is a retrospective cohort study of consecutive patients treated
with the gas-filled IGB or fluid-filled IGB between October 2015 and May 2020 at 2 academic …

The global obesity epidemic has driven the need for innovative and effective weight
management strategies. Obesity is associated with cardiometabolic diseases which can …

Background Weight regain and inadequate weight loss are common following bariatric
surgery. Literature is emerging regarding the use of pharmacotherapy with bariatric surgery …

Endoluminal metabolic and bariatric therapy represents a bridge between lifestyle
counseling, pharmaceutical interventions, and the most efficacious treatment for obesity …